A Phase I/II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy as Frontline Therapy for Older Patients with ALL
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Nicholas Short, Elias Jabbour, Susan O'Brien, Rita Khouri, Farhad Ravandi, Deborah Thomas, Guillermo Garcia-Manero, Koji Sasaki, Gautam Borthakur, Nitin Jain, Marina Konopleva, Jovitta Jacob, Rebecca Garris, Jorge Cortes, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Blinatumomab is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: the Bologna Compassionate Program Experience
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Cristina Papayannidis, Stefania Paolini, Alessandra Santoro, Valentina Robustelli, Simona Soverini, Caterina De Benedittis, Enrica Imbrogno, Carolina Terragna, Andrea Ghelli Luserna di Rora, Sarah Parisi, Chiara Sartor, Giovanni Marconi, Silvia Lomonaco, Maria Chiara Abbenante, Giovanni Martinelli (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Utility of Day 14 Bone Marrow Evaluation in Adults with Philadelphia Chromosome-Negative ALL: Relationship with Minimal Residual Disease Status
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Nicholas Short, Hagop Kantarjian, Koji Sasaki, Maria Khouri, Jorge Cortes, Farhad Ravandi, Deborah Thomas, Guillermo Garcia-Manero, Issa Khouri, Partow Kebriaei, Richard Champlin, Sherry Pierce, Ghayas Issa, Marina Konopleva, Tapan Kadia, Carlos Bueso-Ramos, Joseph Khoury, Nitin Jain, Susan O'Brien, Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Prognostic Index and Nomogram for Overall Survival (OS) of Adult Patients with Philadelphia-negative B-cell ALL
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Musa Yilmaz, Hagop Kantarjian, Xuemei Wang, Jorge Cortes, Garcia-Manero Garcia-Manero, Rita Khouri, Nicolas Short, Farhad Ravandi, Koji Sasaki, Marina Konopleva, Koichi Takahashi, William Wierda, Nitin Jain, Srdan Verstovsek, Zeev Estrov, Prithviraj Bose, Heather Schroeder, Sherry Pierce, Susan O’Brien, Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Outcomes after Blinatumomab Failure in Patients with Relapsed/ Refractory (R/R) B-cell ALL (ALL)
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Musa Yilmaz, Hagop Kantarjian, Deborah Thomas, Tapan Kadia, Guillermo Garcia-Manero, Rita Khouri, Farhad Ravandi, Gautam Borthakur, Jorge Cortes, Alessandra Ferrajoli, Koji Sasaki, Jane Autry, Rebecca Garris, Kelsey Voit, Susan O’Brien, Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Update Results of Frontline Therapy with Combination of Hyper-CMAD with Liposomal Vincristine (M) in Patients (Pts) with ALL (ALL)
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Koji Sasaki, Elias Jabbour, Susan O'Brien, Maria Khouri, Deborah Thomas, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur, Nicholas Short, Ghayas Issa, Evguenia Gachimova, Rebecca Garris, Jorge Cortes, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Koji Sasaki, Hagop Kantarjian, Deborah Thomas, Farhad Ravandi, Maria Khouri, Jorge Cortes, Naveen Pemmaraju, Tapan Kadia, Nicholas Short, Ghayas Issa, Rebecca Garris, Gal Moore, Vicky Jeanis, Guillermo Garcia-Manero, Gautam Borthakur, William Wierda, Susan O'Brien, Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Propensity Score Analysis: Hyper-CVAD (HCVAD) + Ponatinib vs. HCVAD + Dasatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL)
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Koji Sasaki, Elias Jabbour, Farhad Ravandi, Nicholas Short, Rita Khouri, Deborah Thomas, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Marina Konopleva, Nitin Jain, Ghayas Issa, Vicki Jeanis, Gal Moore, Rebecca Garris, Naveen Pemmaraju, Jorge Cortes, Susan O'Brien, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Outcome of Adult Philadelphia Chromosome-Positive ALL in a Cancer Hospital in East India
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Saurabh Bhave, Anupam Chakrapani, Mayur Parihar, Neeraj Arora, Deepak Mishra, Reena Nair, Mammen Chandy (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Clofarabine Plus Cytarabine Therapy in Fludarabine Refractory Acute Leukemia Patients
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Mehmet Dogu, Ismail Sari, Sibel Hacigoglu, Ali Keskin (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Melissa Mathias, Jonathan Sockolosky, Aaron Chang, Cheng Liu, K. Garcia, David Scheinberg (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

High Frequency of MTHFR, MTR and TC2 Gene Polymorphisms in Guatemalan Children with ALL
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Claudia Carranza, Vanessa Zamora, Mariana Herrera, Luisa Rosales, Mauricio Villegas, Mariela Guerra, Nancy Escobar, Nely Marroquín, Claudia Osorio, Darwin Alvarez, Luis Alvarez (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Complex Karyotype and Low Hypodiploidy/Near Triploidy are Adverse Prognostic Factors in Adult ALL (ALL) Independent of MRD Status
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Ghayas Issa, Hagop Kantarjian, C. Cameron Yin, Wei Qiao, Farhad Ravandi, Rita Khouri, Deborah Thomas, Nicholas Short, Koji Sasaki, Guillermo Garcia-Manero, Tapan Kadia, Jorge Cortes, Naval Daver, Gautam Borthakur, Nitin Jain, Marina Konopleva, Issa Khouri, Partow Kebriaei, Richard Champlin, Sherry Pierce, Susan O’Brien, Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Updated Results from the Phase II Study of Hyper-CVAD in Combination with Ofatumumab as Frontline Therapy for Adults with CD20 Positive (CD20+) ALL
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Ghayas Issa, Hagop Kantarjian, Farhad Ravandi, Deborah Thomas, Maria Khouri, Guillermo Garcia Manero, Rebecca Garris, Jorge Cortes, Nicholas Short, Koji Sasaki, Heather Schroeder, Tapan Kadia, Srdan Verstovsek, Naval Daver, Nitin Jain, Marina Konopleva, Susan O'Brien, Elias Jabbour (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Ponatinib Therapy for Philadelphia-Positive ALL (Ph+ ALL) Patients: Real-World Clinical Practice vs the PACE Trial
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Michael Mauro, Lisa McGarry, Mo Yang, Stephanie Lustgarten, Hui Huang (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Generation of a Quantitative Real Time-Polymerase Chain (Q-PCR) Assay to Identify BCR/ABL1-like ALL Cases
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Sabina Chiaretti, Sara Grammatico, Monica Messina, Alfonso Piciocchi, Anna Fedullo, Valentina Gianfelici, Alessia Lauretti, Grazia Fazio, Maria Martelli, Paola Fazi, Marco Vignetti, Valerio Apicella, Antonella Vitale, Cyril Salek, Gianni Cazzaniga, Anna Guarini, Robin Foà (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

MRD Detection in Egyptian ALL Patients using IGH/TCR Gene Rearrangements as Targets for Real-Time Quantitative PCR: Single Center Experience
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Eman Abdelsalam, Shabaan Radwaan, Hesham Abdelraheem, Taghreed Kamal Eldin, Hosny Badrawy, Mostafa Mohammed Saleh (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Coagulopathy with Chimerism; the Risks of Rituximab
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Hind Rafei, Ivan Garcia (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists Treating Adolescents and Young Adults: A Population-Based Study
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Lori Muffly, Daphne Lichtensztajn, Parveen Shiraz, Theresa Keegan, Scarlett Lin-Gomez (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Acute Tubular Necrosis Secondary to Tyrosine Kinase Inhibitor, Dasatinib, in Philadelphia Chromosome Positive ALL and a Review of the Literature
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Sarmen Sarkissian, Thomas Lee, Ali Amzajerdi, Richard Van Etten (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Clinical Outcome of Acute Lymphocytic Leukemia with Concurrent MLL Gene Rearrangement and t (9; 22) in the Era of Tyrosine Kinase Inhibitors
Publication date: September 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement 2 Author(s): Talha Badar, Hagop Kantarjian, Jorge Cortes, Elias Jabbour, Guillermo Garcia-Manero, Susan O'Brien, Farhad Ravandi (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 20, 2016 Category: Cancer & Oncology Source Type: research

Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation
Conclusion A majority (71%) of DLBCL relapses after auto-HCT are detected by routine surveillance imaging. Overall, there appears to be limited utility for routine imaging after auto-HCT except in select cases where earlier detection and salvage therapy with allogeneic HCT is a potential option. Micro-Abstract A majority (71%) of DLBCL relapses after auto-HCT are detected by routine surveillance imaging. Overall, there appears to be limited utility for routine imaging after auto-HCT except in select cases where earlier detection and salvage therapy with allogeneic HCT is a potential option. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 18, 2016 Category: Cancer & Oncology Source Type: research

Risk of Atrial Fibrillation and Bleeding Diathesis Associated with Ibrutinib Treatment: a Systematic Review and Pooled-Analysis of Four Randomized Controlled Trials
Conclusion The risks of Afib/Aflutter and all-grade bleeding were significantly higher in the ibrutinib group. These results indicate the need for vigilant monitoring while patient is on ibrutinib, and careful assessment of the risks and benefits of anticoagulation. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 18, 2016 Category: Cancer & Oncology Source Type: research

Integrating genomics in myelodysplastic syndrome to predict outcomes after allogeneic hematopoietic cell transplantation
Publication date: Available online 16 September 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Samah Nassereddine, Taiga Nishihori, Eric Padron, Rami Mahfouz, Ali Bazarbachi, Rami S. Komrokji, Mohamed A. Kharfan-Dabaja Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic neoplastic disorders most commonly occurring in the elderly population with a tendency to progress to acute leukemia. Although epigenetic therapies have improved the outcomes of MDS patients, allogeneic hematopoietic cell transplantation (HCT) remains the only curative option for these patients. Molecular characte...
Source: Clinical Lymphoma Myeloma and Leukemia - September 17, 2016 Category: Cancer & Oncology Source Type: research

Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate
Conclusion Prolonged imatinib therapy helps to achieve a deeper molecular response in the long term. Achieving deeper molecular response at any time positively affects maintaining the cytogenetic and molecular responses, decreases the transformation to accelerated and/or blastic phase. The slight prolongation in PFS did not reach statistical significance. Teaser The significance of molecular response depth is not well defined in patients with chronic phase chronic myeloid leukemia (CP-CML) under imatinib treatment. We retrospectively evaluated clinical records of 178 patients with CP-CML. Eighty-eight patients achieved com...
Source: Clinical Lymphoma Myeloma and Leukemia - September 17, 2016 Category: Cancer & Oncology Source Type: research

Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group
Conclusion Current treatments (chemotherapy, immunotherapy and radiotherapy) achieve good control of the disease, with an OS of 5 years in 80% of the patients, although there is no consensus in treatment, given the scarce incidence of these lymphomas. Teaser We reviewed 55 patients diagnosed of primary breast lymphoma, stages IE and IIE, in 16 Spanish institutions. Of the 55 cases, 96,4% correspond to non-Hodgkin lymphoma. Results on 5-year PFS and OS were 73% and 76% respectively. Current treatments achieve good control of the disease, with an OS of 5 years in 80% of the patients. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 17, 2016 Category: Cancer & Oncology Source Type: research

Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management
Publication date: Available online 17 September 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Jorge E. Cortes, Carlos A. Jimenez, Michael J. Mauro, Alex Geyer, Javier Pinilla-Ibarz, B. Douglas Smith Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and managem...
Source: Clinical Lymphoma Myeloma and Leukemia - September 17, 2016 Category: Cancer & Oncology Source Type: research

Survival Analyses and Prognosis of Plasma Cell Myeloma and Plasmacytoma-Like Post-Transplant Lymphoproliferative Disorders
Conclusions Age at diagnosis, elevated creatinine, Caucasian race and OKT3 were associated with inferior survival in patients with PTLD-MM. Survival of PTLD-MM is inferior to SEER-MM, though significant improvements in survival have been documented. Teaser Multiple myeloma developing after solid organ transplant represents a rare form of post-transplant lymphoproliferative disorder (PTLD-MM) that has been incompletely studied. 212 of such patients were identified in a large database and overall survival and prognostic factors examined and compared to multiple myeloma controls derived from SEER. PTLD-MM caries a worse progn...
Source: Clinical Lymphoma Myeloma and Leukemia - September 17, 2016 Category: Cancer & Oncology Source Type: research

Predictive & amp; Prognostic Implications of Variant Philadelphia Translocations in CML – Experience from a Tertiary Oncology Centre in Southern India
Conclusion This is a largest series of variant translocations in CML-CP, pertaining to Indian population. Our data suggests that presence of variant Ph translocations in CML has no significant impact in predicting response to imatinib as well as in prognosticating survival. Teaser Chronic myeloid leukemia with variant translocation in imatinib era has been an area of research regarding its predictive and prognostic effect with current treatment. Our data confirms that use of imatinib overcomes the negative prognostic effect of these translocations giving similar response rates and survival outcomes. (Source: Clinical Lymph...
Source: Clinical Lymphoma Myeloma and Leukemia - September 17, 2016 Category: Cancer & Oncology Source Type: research

Outcome of Adolescents and Young Adults Compared to Pediatric Patients with Acute Myeloid and Promyelocytic Leukemia
Conclusion Our analysis shows AYAs with AML have worse EMR and OS compared to pAML. AYAs with APL and pAPL patients have similar outcomes. To our knowledge, this is the first study reporting outcomes of AYAs and pediatric APL patients using large population based registry with comparison to same age AML patients. Teaser Studies on outcome of adolescents and young adults (AYAs) with acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) are limited. We compared outcomes of AYAs (19-30 years) and pediatric (0-18 years) AML and APL patients using SEER-18 registry. AYAs with AML have worse early mortality and over...
Source: Clinical Lymphoma Myeloma and Leukemia - September 17, 2016 Category: Cancer & Oncology Source Type: research

Acute leukemia characteristics are different around the world: the Mexican perspective
Conclusion ALL is equally frequent than AML in patients ≥16 years of age. Ph+ prevalence is less frequent than that reported in literature. AML cases occur in a younger age in comparison to other countries. There is a higher rate of APL amongst our patients compared to other non-Latin American populations. This study is the largest ever performed in Mexico regarding descriptive AL data. Teaser In Mexico there are no large-scale studies regarding acute leukemia epidemiology. This multicenter, retrospective study evaluated 1,018 patients. A similar prevalence for ALL vs. AML was found. Less positivity for the Philadelphia...
Source: Clinical Lymphoma Myeloma and Leukemia - September 17, 2016 Category: Cancer & Oncology Source Type: research

Characteristics and survival outcome analysis of extramedullary involvement in adult patients with t(8;21) acute myeloid leukemia
Conclusion EM-positive t(8;21) was associated with young age, leukocytosis, and c-kit mutation, and CNS was frequently involved. Allo-HCT showed a feasible outcome for EM-positive t(8;21). Teaser Extramedullary involvement in acute myeloid leukemia with t(8;21) is not a rare manifestation. Extramedullary involvement has been regarded as a poor prognostic factor although t(8;21) is a favorable-risk karyotype. We analyzed 154 patients and identified extramedullary involvement was associated with young age, leukocytosis, and c-kit mutation. Outcomes were similar after transplantation-based treatment strategy regardless of ext...
Source: Clinical Lymphoma Myeloma and Leukemia - September 17, 2016 Category: Cancer & Oncology Source Type: research

Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin's lymphoma with incomplete response prior to autologous stem cells transplantation
Conclusion IFRT used prior or after ASCT might partially compensate for worse prognostic factors among the overall population; subgroup analysis showed a trend for survival benefit at 3 years in patients with limited stage at relapse and PET positivity prior to ASCT. Teaser We investigated the role of radiotherapy in 73 patients receiving autologous stem cell transplant (ASCT) for relapsed/refractory Hodgkin lymphoma by comparing patients who received peri-transplant RT with patients who received chemotherapy alone. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 17, 2016 Category: Cancer & Oncology Source Type: research

A multicenter retrospective study of mogamulizumab efficacy in adult T-cell leukemia/lymphoma
Conclusion Mogamulizumab improves OS in ATL, although its use in HSCT patients might trigger severe GVHD. Determining the optimal pre-HSCT mogamulizumab treatment regimen is thus a priority. Teaser Mogamulizumab recently became available for the treatment of adult T-cell leukemia/lymphoma (ATL). We conducted a multicenter retrospective study of the efficacy of mogamulizumab in ATL treatment in patients in Japan, and found that mogamulizumab is an effective therapeutic strategy in ATL. There is some concern that the use of mogamulizumab in hematopoietic stem cell transplantation patients might cause severe GVHD. Determining...
Source: Clinical Lymphoma Myeloma and Leukemia - September 17, 2016 Category: Cancer & Oncology Source Type: research

Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate
Conclusion Single-agent oral methotrexate appears to be highly efficacious, resulting in long response durations and minimal toxicity. Micro-Abstract A total of 39 patients were diagnosed with large granular lymphocyte leukemia using stringent diagnostic criteria. Of the 39 patients, 15 (38%) were untreated. Of the remaining 24 patients, 13 were initially treated with prednisolone. The overall response rate (ORR) was 84.6%, and the median duration of response (DOR) was 13.5 months. For the 9 patients who received oral methotrexate, the ORR was 89% and the median DOR was 132.7 months. Five patients received methotrexate aft...
Source: Clinical Lymphoma Myeloma and Leukemia - September 14, 2016 Category: Cancer & Oncology Source Type: research

Clinical and Pathologic Correlation of Increased MYC Gene Copy Number in Diffuse Large B-Cell Lymphoma
Conclusion No significant difference in survival was found between patients with DLBCL with MYC ICN and patients with no MYC aberrations (P = .58). Micro-Abstract Comparison of cases of diffuse large B-cell lymphoma with increased copy number of MYC to those without MYC aberration demonstrated no significant difference in survival (P = .58) for patients treated with rituximab-based regimens. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 11, 2016 Category: Cancer & Oncology Source Type: research

Aberrant p15, p16, p53, and DAPK Gene Methylation in Myelomagenesis: Clinical and Prognostic Implications
Conclusions The current study supports a relevant role for p15, p16, and DAPK hypermethylation in the genesis of the plasma cell neoplasm. DAPK hypermethylation also might be an important step in the progression from MGUS to MM. Micro-Abstract Aberrant DNA methylation is important in multiple myeloma pathogenesis. Methylation of p15, p16, p53, and DAPK genes was evaluated in bone marrow (94 patients; 8 controls) by methylation-specific polymerase chain reaction; 63% of patients with multiple myeloma and 39% of patients with monoclonal gammopathy of uncertain significance presented ≥1 hypermethylated gene (P &a...
Source: Clinical Lymphoma Myeloma and Leukemia - September 9, 2016 Category: Cancer & Oncology Source Type: research

Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis
Conclusions CDIH functionally behaves as aggressive NHL despite the fact that under the microscope the lymphomas resemble typical indolent NHLs. These cases seem to fare better when treated with a regimen containing doxorubicin-rituximab. Micro-Abstract We have identified a subset of indolent lymphomas, the presentation of which differs from their expected indolent nature. This subset presents with aggressive features, such as high lactate dehydrogenase, high standardized uptake values, high Ki-67 (> 30%), B symptoms, and unusual areas of involvement (bone, pleura, lung). Although this subset histologically resemble...
Source: Clinical Lymphoma Myeloma and Leukemia - September 8, 2016 Category: Cancer & Oncology Source Type: research

Evaluation of the Impact of Renal Failure on Correlation and Concordance Between 2 Free Light Chain Assays
Conclusions Despite adjusted reference ranges for Freelite FLC ratio, there are approximately 12.5% discrepancies in interpretation of FLC ratio between the 2 available assays. They are not linked to renal failure stage and neither of the assays performed better than the other: results must be interpreted taking into account clinical data and the same assay must be used for patient follow-up. Micro-Abstract Measurement of serum free light chains (FLCs) is recommended for diagnosis of monoclonal gammopathies. FLC measurements with Freelite (Binding Site) and N Latex FLC (Siemens) assays were performed on 1215 fresh sera sam...
Source: Clinical Lymphoma Myeloma and Leukemia - September 8, 2016 Category: Cancer & Oncology Source Type: research

Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
Conclusion CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach. Micro-Abstract Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P...
Source: Clinical Lymphoma Myeloma and Leukemia - September 8, 2016 Category: Cancer & Oncology Source Type: research

Interim PET Scans in Diffuse Large B Cell Lymphoma: is it ready for prime time?
Publication date: Available online 8 September 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Maital Bolshinsky, Chadi Nabhan Prognostication of patients with Diffuse Large B-Cell Lymphoma (DLBCL) has improved in the past decade with a variety of clinical, morphologic, molecular, and radiographic methods. Comparable to data on the value of interim positron emission tomography (PET) in Hodgkin Lymphoma (HL), several retrospective and prospective studies are attempting to assess the value of interim-PET scanning in DLBCL patients. In this review, we briefly describe and analyze the various prognostic methods ...
Source: Clinical Lymphoma Myeloma and Leukemia - September 7, 2016 Category: Cancer & Oncology Source Type: research

Richter ’s Transformation in the Era of Kinase Inhibitor Therapy: A Review
Publication date: Available online 8 September 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Emily C. Ayers, Anthony Mato Richter’s transformation (RT) is the transformation of chronic lymphocytic leukemia (CLL) into rapidly progressive b-cell lymphoma. This disease has long been recognized as a difficult-to-treat illness with poor survival outcomes. While the incidence of RT has been well documented in prior literature, less is understood in the era of novel therapeutics, namely, kinase inhibitors (KI). This review discusses the current risk factors, incidence, and outcomes of patients with RT in th...
Source: Clinical Lymphoma Myeloma and Leukemia - September 7, 2016 Category: Cancer & Oncology Source Type: research

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia
Conclusion The favorable-risk cohort had better RFS and OS compared to the outcomes of patients in the intermediate- and adverse-risk cohorts; the RFS and OS did not differ between intermediate- and adverse-risk cohorts. The presence of AHD did not affect OS. Micro-Abstract The presence of antecedent hematologic disorders at diagnosis of therapy-related acute myeloid leukemia did not affect overall survival (OS). The favorable-risk cohort had better relapse-free survival (RFS) and OS compared to the outcomes of patients in the intermediate and adverse-risk cohorts; the RFS and OS did not differ between intermediate- and ad...
Source: Clinical Lymphoma Myeloma and Leukemia - September 3, 2016 Category: Cancer & Oncology Source Type: research

Key Molecular Drivers of Chronic Lymphocytic Leukemia
Publication date: Available online 10 August 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Suliman A. Alsagaby, Paul Brennan, Chris Pepper Chronic lymphocytic leukemia (CLL) is an adult neoplastic disease of B cells characterized by variable clinical outcomes. Although some patients have an aggressive form of the disease and often encounter treatment failure and short survival, others have more stable disease with long-term survival and little or no need for theraphy. In the past decade, significant advances have been made in our understanding of the molecular drivers that affect the natural pathology of C...
Source: Clinical Lymphoma Myeloma and Leukemia - September 3, 2016 Category: Cancer & Oncology Source Type: research

Polyclonal Localized Light Chain Amyloidosis —A Distinct Entity?
Publication date: Available online 10 August 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Aishwarya Ravindran, Karen L. Grogg, David A. Domaas, Ronald S. Go (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - September 2, 2016 Category: Cancer & Oncology Source Type: research

Survival Rates of Adults With Acute Lymphoblastic Leukemia in a Low-Income Population: A Decade of Experience at a Single Institution in Mexico
Conclusion Adults with ALL in Mexico had high-risk characteristics and an increased relapse rate; however, the OS after CR was similar to the greatest achieved in developed countries, suggesting that a threshold for curing adult ALL with current therapeutic strategies has been reached. Micro-Abstract Adult acute lymphoblastic leukemia has an elevated mortality rate, with little improvement in recent decades. We studied 94 patients treated over 10 years in a low-income population. Younger age, elevated high-risk disease, and a high relapse rate were documented. However, overall survival after complete remission was close to...
Source: Clinical Lymphoma Myeloma and Leukemia - September 2, 2016 Category: Cancer & Oncology Source Type: research

Total Skin Electron Beam Therapy in the Treatment of Mycosis Fungoides: a review of Conventional and Low-Dose Regimens
Publication date: Available online 29 August 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Mudit Chowdhary, Arpit M. Chhabra, Shivam Kharod, Gaurav Marwaha Mycosis fungoides (MF) is the most prevalent subtype of cutaneous T-cell lymphoma, which is characterized by the proliferation of CD4+ T-cells. While often an indolent disease, most patients eventually develop progression from isolated patches to tumors and finally nodal or visceral involvement. Treatment choice is largely based on disease burden, though prognostic factors such as disease stage, patient age, and extra-cutaneous involvement must be taken...
Source: Clinical Lymphoma Myeloma and Leukemia - August 29, 2016 Category: Cancer & Oncology Source Type: research

Impact of routine surveillance imaging on the outcomes of patients with diffuse large B-cell lymphoma following autologous hematopoietic cell transplantation
Conclusion In conclusion, a majority (71%) of DLBCL relapses after auto-HCT are detected by routine surveillance imaging. Overall there appears to be limited utility for routine imaging post auto-HCT except in select cases where earlier detection and salvage with allogeneic HCT is a potential option. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 29, 2016 Category: Cancer & Oncology Source Type: research

Increased bone marrow iron scores (BMIS) are strongly correlated with elevated serum ferritin levels and poorer survival in patients with iron overload that underwent allogeneic hematopoietic stem cell transplantation (alloHSCT): A single center experience
Conclusion The validation of BMIS for risk stratification in patients who undergo allogeneic hematopoietic stem cell transplantation may predict post-transplant outcomes. Teaser Iron overload (IO) is one of the most important complications of chronic red blood cell transfusions in patients that receive chemotherapy or undergo hematopoieteic stem cell transplantation (HSCT). Bone marrow is among the major sites of IO. So; this study showed that increased bone marrow iron content might predict poor survival in alloHSCT recipients and that bone marrow evaluations prior to transplantation would be a valuable method to diagnose...
Source: Clinical Lymphoma Myeloma and Leukemia - August 23, 2016 Category: Cancer & Oncology Source Type: research

Clinical and pathological correlation of increased MYC gene copy number in diffuse large B-cell lymphoma (DLBCL)
In this study, we found no significant difference in survival between cases of DLBCL with MYC ICN and cases with no MYC aberrations (p=0.58). Teaser Comparison of cases of DLBCL with increased copy number of MYC to those without MYC aberration demonstrated no significant difference in survival (p=0.58) for patients treated with Rituximab based regimens. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 20, 2016 Category: Cancer & Oncology Source Type: research